Research field (1):
Tumor diagnostics and therapeutics
Research theme for competitive and other funds (1):
2022 - 2025 Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors
Papers (83):
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. The Journal of clinical investigation. 2024. 134. 7
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno, et al. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. British journal of cancer. 2024
Satoru Hagiwara, Junko Tanizaki, Hidetoshi Hayashi, Yoriaki Komeda, Naoshi Nishida, Akihiro Yoshida, Tomoki Yamamoto, Takuya Matsubara, Masatoshi Kudo. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer reports (Hoboken, N.J.). 2024. e1960
Junko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, Makoto Takahama, Hiroyasu Shoda, Atsushi Nakamura, Yoshitaka Kitamura, Nobuaki Mamesaya, Yoshihisa Kadota, Kenji Sawa, et al. Lack of Association of Plasma Levels of Soluble PD-1, PD-L1, and CTLA-4 with Survival for Stage II to IIIA Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy. JTO Clinical and Research Reports. 2023. 100590-100590
米阪仁雄, 稲垣千昌, 稲垣千昌, 高濱隆幸, 高濱隆幸, 白石直樹, 磯本晃佑, 金村宙昌, 鈴木慎一郎, 谷崎潤子, et al. Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling. 日本癌学会学術総会抄録集(Web). 2023. 82nd